4SG.F SOL-GEL TECHN. IS-10

Healthcare Biotechnology Frankfurt Exchange
54.00 EUR
Close of Nov 11, 2026
28.80 82.00
Market cap
EUR 177M
P/E
-
P/B
4.01x
ROE
-30.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 4SG.F undervalued?

Graham number

The Graham number of SOL-GEL TECHN. IS-10 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SOL-GEL TECHN. IS-10 fundamental analysis

No fundamental analysis for SOL-GEL TECHN. IS-10 yet.

SOL-GEL TECHN. IS-10 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SOL-GEL TECHN. IS-10

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in…

Full company profile